The University of Chicago Header Logo

Connection

Michael Thirman to Peptide Elongation Factors

This is a "connection" page, showing publications Michael Thirman has written about Peptide Elongation Factors.
Connection Strength

0.993
  1. ELL and EAF1 are Cajal body components that are disrupted in MLL-ELL leukemia. Mol Biol Cell. 2003 Apr; 14(4):1517-28.
    View in: PubMed
    Score: 0.194
  2. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol Cell Biol. 2001 Aug; 21(16):5678-87.
    View in: PubMed
    Score: 0.173
  3. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood. 2001 Jul 01; 98(1):201-9.
    View in: PubMed
    Score: 0.172
  4. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci U S A. 2000 Sep 26; 97(20):10984-9.
    View in: PubMed
    Score: 0.163
  5. Developmental analysis and subcellular localization of the murine homologue of ELL. Proc Natl Acad Sci U S A. 1997 Feb 18; 94(4):1408-13.
    View in: PubMed
    Score: 0.127
  6. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc Natl Acad Sci U S A. 1994 Dec 06; 91(25):12110-4.
    View in: PubMed
    Score: 0.109
  7. The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions. Mol Endocrinol. 2005 May; 19(5):1158-69.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.